Cantargia AB (CANTA) Price & Analysis

Compare

2 Followers

CANTA Stock Chart & Stats

kr4.04

-kr0.02(-1.25%)

At close: Mar 06 4:00 PM EST

kr4.04

-kr0.02(-1.25%)

Day’s Range― - ―

52-Week Rangekr1.00 - kr4.78

Previous CloseN/A

Volume611.88K

Average Volume (3M)1.42M

Market Cap

€815.45M

Enterprise Valuekr276.13M

Total Cash (Recent Filing)€339.14M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Feb 20, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.07

Shares Outstanding248,611,650

10 Day Avg. Volume1,074,033

30 Day Avg. Volume1,417,172

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)2.67

Price to Sales (P/S)0.00

P/FCF Ratio-1.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€14.05

Price Target Upside247.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market PotentialThere are currently no approved bispecifics in the autoimmune space, providing a significant market opportunity for the company.

Pipeline DevelopmentPreclinical pipeline advancement continues across oncology and immunology with the development of next-generation anti-IL1RAP antibodies.

Strategic PartnershipsThe CAN10 program acquisition by Otsuka Pharmaceutical provides important external validation and immediate non-dilutive financing to Cantargia.

Bears Say

Clinical Trial FailuresThe final median overall survival (OS) data from the TRIFOUR study confirmed the program's failure in triple-negative breast cancer (TNBC), justifying our prior zero valuation contribution for this indication.

Efficacy ConcernsThe updated survival data from the Phase 1b/2 TRIFOUR study serve as the final confirmation of the program's lack of efficacy in TNBC.

Endpoint MissThe TRIFOUR Phase 2 study in TNBC did not meet its primary ORR endpoint, comparing nadunolimab in combination with chemotherapy vs. chemotherapy alone.

Cantargia AB News

Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback

H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Cantargia AB today and set a price target...

7d ago

Cantargia Reports TRIFOUR Study Results on Nadunolimab

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB announced that the TRIFOUR study, evaluating nadunolimab...

8d ago

Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating

Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Cantargia AB, retaining the price target of...

23d ago

Cantargia AB Releases Interim Report Highlighting Strategic Progress

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has released its interim report...

24d ago

Cantargia AB Announces Nomination Committee for 2026 AGM

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia AB has announced the appointment of its Nomination...

1M ago

Cantargia AB to Release Interim Report and Host Investor Presentation

The latest announcement is out from Cantargia AB ( ($SE:CANTA) ). Cantargia AB announced the release of its...

1M ago

Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating

Sara Nik, an analyst from H.C. Wainwright, has initiated a new Buy rating on Cantargia AB (7V3). Sara...

2M ago

Cantargia AB to Present at Key Investor Conferences

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB announced its participation in upcoming investor conferences,...

2M ago

Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia AB has appointed Dr. Wolfram Dempke as its...

2M ago

Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million

An announcement from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has completed the sale of...

3M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.00 and its highest was kr4.78 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is €815.45M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 69 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on Nov 19, 2025. The company reported kr1.07 earnings per share for the quarter, beating the consensus estimate of -kr0.17 by kr1.24.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.19.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 248,611,650 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of kr1.07 in its last earnings report, beating expectations of -kr0.17. Following the earnings report the stock price went down -7.445%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

Company Description

Cantargia AB

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

Cantargia AB (CANTA) Earnings & Revenues

Historic Earnings Reports

CANTA Stock 12 Month Forecast

Average Price Target

kr14.05

▲(247.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","15":"kr15","3.75":"kr3.75","7.5":"kr7.5","11.25":"kr11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.05063786990122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr14.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.0539716027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr14.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.05063786990122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr14.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.225,4.980818297684709,5.7366365953694185,6.492454893054127,7.2482731907388365,8.004091488423546,8.759909786108254,9.515728083792965,10.271546381477673,11.027364679162382,11.783182976847092,12.5390012745318,13.29481957221651,{"y":14.05063786990122,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.225,4.98107473866923,5.737149477338461,6.493224216007692,7.249298954676923,8.005373693346154,8.761448432015385,9.517523170684616,10.273597909353846,11.029672648023077,11.785747386692307,12.541822125361538,13.29789686403077,{"y":14.0539716027,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.225,4.980818297684709,5.7366365953694185,6.492454893054127,7.2482731907388365,8.004091488423546,8.759909786108254,9.515728083792965,10.271546381477673,11.027364679162382,11.783182976847092,12.5390012745318,13.29481957221651,{"y":14.05063786990122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.874,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.719,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.43,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.272,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.406,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.235,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.63,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >